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Table 3 Study design for intravaginal ring size-fitting in pig-tailed and Chinese rhesus macaques 
Size-fitting IVR for Macaques 
ring observed to be in place (colposcopy) and no adverse effects or behavioral issues/problems noted, based on daily 
monitoring    CVL - cervicovaginal lavage      P-Blood collected for plasma 
Figure 2  IVRs do not induce expression of pro-inflammatory markers   A) Pro-inflammatory cytokines are plotted for each 
individual animal during the course of the study  B) Scatter plots for each cytokine were plotted for all 4 macaques before IVR 
was inserted (pre); in the presence of the IVR (IVR); and after removal of the IVR (post).   
Results
?As assessed by physical examination, colposcopy and behavioral observation, the 25mm rings were well 
tolerated by both Chinese rhesus and pig-tailed macaques.
?Levels of pro-inflammatory cytokine markers from cervicovaginal lavages remained stable throughout the 
study period of 8 weeks   
Conclusions
?Silicone-based rings of 25mm diameter are easily inserted into the vaginal vault of both Chinese Rhesus 
and pig-tailed macaques and their presence does not alter the behavior of the animals or induce 
inflammation. These results warrant further studies utilizing IVRs loaded with antiviral drugs in the non-
human primate model.   
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1 Viral replication in PBMC and monocytes/macrophage cultures were determined on day 7 post-infection by measuring supernatant reverse 
transcriptase (RT) activity or p24 antigen expression by ELISA. Units are in µM.     EC50 - high antiviral activity (low EC50), IC50 - low cellular toxicity 
(high IC50), TC50 – low cellular toxicity (high TC50), TI – Therapeutic index = IC50 or TC50 / EC50
Table 5  Comparison of ZFI release rates and physicochemical properties; compounds presented in order of decreasing release rate.
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Figure 4   Matrix-type IVRs were loaded with 50mg of ZFI 52, 89 or 122. Release was determined by HPLC analysis of drug levels in 
media under sink conditions. A) daily release-versus-time profiles  B) mean cumulative release-versus-time profiles   C) mean 
cumulative release-versus-root time
* equal to the gradient of cumulative release versus root time profile, where A is the drug loading per unit volume, S is the surface area of the ring, D is 
the apparent diffusion coefficient, and C is the silicone elastomer solubility per unit volume of the active agent.
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Results
?The daily and cumulative release profiles (Fig 4) are typical of diffusion-controlled matrix-type devices, showing 
an initial Day 1 burst followed by a declining daily release rate on subsequent days. Daily release rates range 
from 20-300 mcg/day. 
?Compound 89 released at the fastest rate, followed by Compound 52, and Compound 122 the slowest
?The almost perfect straight-line plots of the cumulative release-versus-root time are indicative of t 0.5 kinetics, 
confirming diffusion-controlled release from a matrix delivery system
Conclusions
Disclaimer The findings and conclusions in this presentation have not been formally disseminated by [the Centers for Disease Control and 
Prevention/the Agency for Toxic Substances and Disease Registry] and should not be construed to represent any agency determination or policy.
In several independent studies, the utility and acceptance of intravaginal rings as a delivery device for hormones 
and contraception has been well documented.  The controlled sustained release of inhibitors from IVRs for pre-
exposure prophylaxis has many of the desired characteristics of an ideal vaginal microbicide.  This study was 
launched to adapt and expand this versatile delivery device to the non-human primate model of HIV prevention.  
The fact that IVR did not cause inflammation and the zinc finger inhibitor was successfully released makes this 
combination, as well as other classes of HIV inhibitors, an excellent candidate for preclinical evaluation in the 
non-human primate repeat challenge model.
In Vitro Release of Zinc Finger Inhibitors
Figure 3  Zinc finger inhibitors are thioester-based compounds that interfere with the interaction of the nucleocapsid protein (NCp7) of 
SIV and HIV with zinc molecules. 
Table 4 In vitro inhibition of replication against SIV and HIV-1 with ZFI compounds (Adapted from: Srivastava, P. et. al. 
Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorg Med Chem 2004, 12, (24), 6437-50)
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Background: Small molecule inhibitors of the zinc finger domain (ZFI) in the nucleocapsid protein (NCp7) of HIV-1 are potent inhibitors of HIV and SIV 
replication and may have utility as topical products to prevent infection. Furthermore, intravaginal rings (IVRs) were developed as coitally-independent, 
sustained release devices which could be used for administration of HIV microbicides. The aims of these studies were to demonstrate that IVRs sized for 
macaques are practical and compatible with the current generation of thioester-based NCp7 inhibitors. 
Methods: Non-medicated silicone elastomer vaginal rings of various sizes thought to be applicable for macaques were prepared and tested for vaginal fit in 
Pigtailed and Chinese Rhesus macaques. Macaques were monitored for 8 weeks for mucosal disruption by colposcopy and proinflammatory cytokine markers 
in cervical vaginal lavages (CVL) using Luminex bead-based technology.  Three different ZFIs (compounds 52, 89 and 122, each derived from an N-substituted 
S-acyl-2-mercaptobenzamide thioester scaffold) were loaded at 50 mg into an optimal matrix-type ring design. In vitro continuous release studies were then 
conducted over 28 days and analyzed by HPLC. Rate of release was determined by linear regression analysis.
Results: Qualitative evaluation at the time of ring insertion suggested that the 25 mm ring provided optimal fit in both macaque species. All rings remained in 
place during the study period (2 to 4 weeks), and the animals did not attempt to remove the rings. No tissue irritation was observed, and no signs of physical 
discomfort were noted. Also, no significant induction of cervicovaginal proinflammatory markers was observed during the 8-week period during and following 
ring insertion. One Pigtailed macaque showed elevated IL-8 levels in the CVL during the period when the ring was in place; however, these levels were 
comparable to those observed in two control macaques. In vitro release of the ZFIs peaked at day 1 and then continually declined to near steady-state rates 
between 20-30 mcg/day. The percent release after 14 days was 2.9, 2.0 and 0.9 for ZFI 89, 52 and 122, respectively.
Conclusions: IVRs of 25mm diameter, determined to be the optimal size for macaques, were well tolerated and did not induce inflammation. Release of all ZFI 
compounds followed t 0.5 kinetics. These findings suggest that efficacy testing in primate models is warranted to fully evaluate the potential to prevent 
transmission.
Abstract
Introduction
The HIV pandemic can arguably be best slowed and eventually stopped by an effective vaccine. Although great strides have been made 
towards that end, an effective vaccine is realistically still many years away, providing a compelling argument for the exploration of other 
avenues of HIV prevention.  Currently, there are a handful of effective microbicides that are designed to prevent HIV transmission by targeting 
specific viral proteins and hindering viral replication.  Many of these compounds can potentially inhibit replication of HIV at the site of exposure 
and are, therefore, especially important to female sex workers and women in heterosexual relationships.
NCp7 is involved in both the early phase (facilitating reverse transcription and mediating undefined effects on integration) and the late phase 
(incorporation of the viral RNA genome into newly budding particles) of virus replication. HIV NCp7 contains two highly conserved zinc finger 
motifs that form an ordered and unique structure. Single amino acid mutations introduced within chelating (CCHC) or specific non-chelating 
residues of the zinc fingers result in the production of noninfectious virus particles. The potential virucidal nature of ZFI and the ability to inhibit 
cell-cell transmission together with the large number of conserved residues within the structure among HIV strains makes the NCp7 target 
highly desirable for microbicide applications.
The characteristics of an ideal vaginal microbicide are summarized in Table 1.  Although many of the available antiviral drugs and compounds 
are highly effective, delivery and retention of the microbicide at the mucosal surface is challenging. Currently, the major challenges include the 
need to constantly reapply the microbicide gels and that gels are not universally received by all cultures. Therefore, there is a great need for an 
effective microbicide delivery device that will afford protection, is easy to use and socially and culturally acceptable.
Intravaginal rings (IVRs) are widely accepted and currently being used as contraceptive devices for the long-term, controlled release of 
hormones (Table 2). Adapting IVRs for sustained delivery of microbicides against HIV seems a logical progression of this technology since they 
possess many of the desirable attributes listed in Table 1. We describe the adaptation of this technology to the non-human primate model for 
studying HIV transmission, and report the initial in vitro release of a class of investigative drugs, zinc finger inhibitors.
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Table 2  Vaginal rings either marketed or in development [Adapted from Woolfson et. al. Potential Use of Vaginal Rings for Prevention of 
Heterosexual Transmission of HIV Am J Drug Deliv 2006; 4 (1)]
Table 1   Characteristics of an ideal vaginal HIV microbicide product [Woolfson et. al. Potential Use of Vaginal Rings for Prevention of 
Heterosexual Transmission of HIV Am J Drug Deliv 2006; 4 (1)] 
1 HRT – Hormone replacement therapy
Figure 1  Types of silicone-based intravaginal rings  IVRs can be manufactured to release drug at constant levels (reservoir) or at a high initial 
level with a decreasing release rate over time (matrix). 
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Ability to be used without knowledge of male partnerRetain activity in presence of semen
Long duration of activityTake account of physiological changes that occur during  intercourse
NonteratogenicGood vaginal distribution
OdorlessGood vaginal retention
TastelessNon-messy
Availability of contraceptive and noncontraceptive formsMaintain the integrity of the vaginal tissue
High user acceptabilityCause no local irritancy
Negligible systemic absorptionLong shelf-life
Compatible with condomsImmediate protection after application
Activity against other sexually transmitted pathogensCause no physical discomfort
Maintain normal vaginal ecologyEase of application
Retain activity over broad pH rangeInexpensive to manufacture
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